Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CS1-directed monoclonal antibody therapy for multiple myeloma.

× No keyword cloud information.

9 in total

1. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Authors: Don M Benson; Adam D Cohen; Sundar Jagannath; Nikhil C Munshi; Gary Spitzer; Craig C Hofmeister; Yvonne A Efebera; Pascale Andre; Robert Zerbib; Michael A Caligiuri
Journal: Clin Cancer Res Date: 2015-05-21 Impact factor: 12.531

2. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.

Authors: Jianhong Chu; Shun He; Youcai Deng; Jianying Zhang; Yong Peng; Tiffany Hughes; Ling Yi; Chang-Hyuk Kwon; Qi-En Wang; Steven M Devine; Xiaoming He; Xue-Feng Bai; Craig C Hofmeister; Jianhua Yu
Journal: Clin Cancer Res Date: 2014-03-27 Impact factor: 12.531

3. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells.

Authors: Yufeng Wang; Yibo Zhang; Tiffany Hughes; Jianying Zhang; Michael A Caligiuri; Don M Benson; Jianhua Yu
Journal: Clin Cancer Res Date: 2018-04-17 Impact factor: 12.531

Review 4. Multiple myeloma-initiating cells.

Authors: Naoki Hosen
Journal: Int J Hematol Date: 2013-02-19 Impact factor: 2.490

Review 5. Present and Future of Allogeneic Natural Killer Cell Therapy.

Authors: Okjae Lim; Mi Young Jung; Yu Kyeong Hwang; Eui-Cheol Shin
Journal: Front Immunol Date: 2015-06-03 Impact factor: 7.561

6. Combination immune therapies to enhance anti-tumor responses by NK cells.

Authors: Ashley Mentlik James; Adam D Cohen; Kerry S Campbell
Journal: Front Immunol Date: 2013-12-23 Impact factor: 7.561

7. A compound chimeric antigen receptor strategy for targeting multiple myeloma.

Authors: K H Chen; M Wada; K G Pinz; H Liu; X Shuai; X Chen; L E Yan; J C Petrov; H Salman; L Senzel; E L H Leung; X Jiang; Y Ma
Journal: Leukemia Date: 2017-09-27 Impact factor: 11.528

8. CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon.

Authors: Kai-Lin Xu; Hai Cheng
Journal: Blood Sci Date: 2019-10-21

9. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Authors: J Chu; Y Deng; D M Benson; S He; T Hughes; J Zhang; Y Peng; H Mao; L Yi; K Ghoshal; X He; S M Devine; X Zhang; M A Caligiuri; C C Hofmeister; J Yu
Journal: Leukemia Date: 2013-09-26 Impact factor: 11.528

9 in total